PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
This approval has come from the company's finished dosage form manufacturing facility
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
Lutio has the potential to offer significant cost savings when available to UK patients.
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
